Answers are grounded in this paper and cite their sources.
range, significantly enhanced drug solubility. In vitro assays on SH-SY5Y cells demonstrated low cytotoxicity at short incubation times confirming that drug release and cellular uptake depend on CD binding affinity. In vivo biodistribution analysis through boron quantification by ICP-MS in C57BL/6 mice exhibit that intranasal administration achieves effective brain targeting while reducing systemic exposure compared to the intravenous one. Interestingly, the BMAC-9/HP-β-CD complex showed selective accumulation in Aβ plaque-rich brain areas only in APP/PS1dE9 transgenic mice. This selectivity is crucial for BNCT efficacy and offers a promising solution to the persistent challenge of targeted drug delivery in neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Alberti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: